Portal de Periódicos da CAPES

Severe Intraocular Inflammation Following Intravitreal Faricimab

2024; American Medical Association; Volume: 142; Issue: 4 Linguagem: Inglês

10.1001/jamaophthalmol.2024.0530

2168-6173

Loka Thangamathesvaran, Jun Kong, Susan B. Bressler, Mandeep S. Singh, Adam S. Wenick, Adrienne W. Scott, J. Fernando Arévalo, Neil M. Bressler,

Retinal Diseases and Treatments

Monitoring for and reporting potential cases of intraocular inflammation (IOI) in clinical practice despite limited occurrences in clinical trials, including experiences with relatively new intravitreal agents, such as brolucizumab, pegcetacoplan, or faricimab, helps balance potential benefits and risks of these agents.